Lanean...
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
INTRODUCTION: Renal cell carcinoma (RCC) represents 2%–3% of all cancers in adults, and its pathogenesis is mainly related to altered cellular response to hypoxia. Lenvatinib, a novel multitarget tyrosine kinase inhibitor (TKI), represents a therapeutic option, in combination with mammalian target o...
Gorde:
| Argitaratua izan da: | Ther Clin Risk Manag |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Dove Medical Press
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5499780/ https://ncbi.nlm.nih.gov/pubmed/28721060 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S126910 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|